Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan;45(1):12-7.
doi: 10.1038/ng.2493. Epub 2012 Dec 2.

Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma

Mark Sausen  1 , Rebecca J Leary, Siân Jones, Jian Wu, C Patrick Reynolds, Xueyuan Liu, Amanda Blackford, Giovanni Parmigiani, Luis A Diaz Jr, Nickolas Papadopoulos, Bert Vogelstein, Kenneth W Kinzler, Victor E Velculescu, Michael D Hogarty
Affiliations

Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma

Mark Sausen et al. Nat Genet. 2013 Jan.

Abstract

Neuroblastomas are tumors of peripheral sympathetic neurons and are the most common solid tumor in children. To determine the genetic basis for neuroblastoma, we performed whole-genome sequencing (6 cases), exome sequencing (16 cases), genome-wide rearrangement analyses (32 cases) and targeted analyses of specific genomic loci (40 cases) using massively parallel sequencing. On average, each tumor had 19 somatic alterations in coding genes (range of 3-70). Among genes not previously known to be involved in neuroblastoma, chromosomal deletions and sequence alterations of the chromatin-remodeling genes ARID1A and ARID1B were identified in 8 of 71 tumors (11%) and were associated with early treatment failure and decreased survival. Using tumor-specific structural alterations, we developed an approach to identify rearranged DNA fragments in sera, providing personalized biomarkers for minimal residual disease detection and monitoring. These results highlight the dysregulation of chromatin remodeling in pediatric tumorigenesis and provide new approaches for the management of patients with neuroblastoma.

PubMed Disclaimer

Conflict of interest statement

COMPETING FINANCIAL INTERESTS

L.A.D., N.P., B.V., K.W.K., and V.E.V are founders of Inostics and Personal Genome Diagnostics and are members of their Scientific Advisory Boards. L.A.D., N.P., B.V., K.W.K., and V.E.V. own Inostics and Personal Genome Diagnostics stock, which is subject to certain restrictions under university policy. The terms of these arrangements are managed by Johns Hopkins University in accordance with its conflict-of-interest policies.

Figures

Figure 1
Figure 1. Number and type of somatic alterations detected in each neuroblastoma case
The vertical axis includes non-synonymous single base substitutions, insertions, deletions, and splice site changes (NS Mutations), homozygous deletions and amplifications affecting protein encoding genes, and rearrangements with at least one breakpoint within the coding region of a gene. The inset shows the mutation spectra of somatic non-silent single nucleotide mutations in 16 cases of neuroblastoma. Data on rearrangements and copy number changes were not available for starred samples.
Figure 2
Figure 2. Genomic alterations in ARID1A and ARID1B
The schematic represents the ARID1B and ARID1A proteins with the predicted effects of observed intragenic deletions and point mutations.
Figure 3
Figure 3. Overall survival according to ARID1 status
The hazard ratio for death among patients with wildtype ARID1B/A (n=48), as compared to those with mutant ARID1B/A (n = 7) was 4.49 (95% confidence interval, CI 1.24–16.33; P=0.0226, log-rank test). The median survival was 1689 days for patients with wildtype ARID1B/A compared to 386 days for patients with mutated ARID1B/A. An analysis that also included hemizygous deletions of the entire coding region of ARIDB further increased the significance of the survival difference between patients with mutant and wildtype ARID1B/A (hazard ratio, HR 6.41; 95% confidence interval, CI 1.93–21.25; P=0.0024, log-rank test).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ries LAG, SM, Gurney JG, Linet M, Tamra T, Young JL, Bunin GR. NIH Publication. 99-4649. National Cancer Institute, SEER Program; Bethesda, MD: 1999. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975–1995.
    1. Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362:2202–11. - PMC - PubMed
    1. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369:2106–20. - PubMed
    1. Capasso M, Diskin SJ. Genetics and genomics of neuroblastoma. Cancer Treat Res. 2010;155:65–84. - PubMed
    1. Mueller S, Matthay KK. Neuroblastoma: biology and staging. Curr Oncol Rep. 2009;11:431–8. - PubMed

Publication types

Associated data